secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273342
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.03, 2.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors
--------------------------------------------------------------------------------

- Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
- Concurrent PIPE of ~$285M via sale of 39,641 Series C preferred shares; closing expected Nov 12, 2025.
- Board replaced: Anne Prener, David Shapiro, Amy Wechsler resigned; Peter Harwin, Chris Cain, Julianne Bruno (Fairmount) appointed.
- Executive retention bonuses: CEO (DKK 2,173,800 target), CFO ($112,500), GC ($161,160); CFO salary increased to $375,000.
- Series B & C preferred are non-voting, convertible 1:1,000 into common, subject to stockholder approval and ownership caps.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/0001193125-25-273342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000119312525273342/d53983d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer